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ABSTRACT SeveralrecentstudieshaveconvergedupontheinnateimmuneDNAcytosinedeaminaseAPOBEC3B(A3B)asasig-
niﬁcantsourceofgenomicuracillesionsandmutagenesisinmultiplehumancancers,includingthoseofthebreast,head/neck,
cervix,bladder,lung,ovary,andothertissues. A3Bisupregulatedinthesetumortypesrelativetonormaltissues,butthemecha-
nismisunclear.BecauseA3Balsohasantiviralactivityinmultiplesystemsandisamemberofthebroaderinnateimmunere-
sponse,wetestedthehypothesisthathumanpapillomavirus(HPV)infectioncausesA3Bupregulation.Wefoundthat A3B
mRNAexpressionandenzymaticactivitywereupregulatedfollowingtransfectionofahigh-riskHPVgenomeandthatthiseffect
wasabrogatedbyinactivationofE6.TransductionexperimentsshowedthattheE6oncoproteinalonewassufﬁcienttocause
A3Bupregulation,andapanelofhigh-riskE6proteinstriggeredhigher A3Blevelsthandidapaneloflow-riskornoncancerE6
proteins.KnockdownexperimentsinHPV-positivecelllinesshowedthatendogenous E6isrequiredforA3Bupregulation.Anal-
ysesofpubliclyavailablehead/neckcancerdatafurthersupportthisrelationship,as A3BlevelsarehigherinHPV-positivecan-
cersthaninHPV-negativecancers.Takentogetherwiththeestablishedroleforhigh-riskE6infunctionalinactivationofTP53
andpublishedpositivecorrelationsinbreastcancerbetween A3Bupregulationandgeneticinactivationof TP53,ourstudies
suggestamodelinwhichhigh-riskHPVE6,possiblythroughfunctionalinactivationofTP53,causesderepressionof A3Bgene
transcription.ThiswouldleadtoamutatorphenotypethatexplainstheobservedcytosinemutationbiasesinHPV-positive
head/neckandcervicalcancers.
IMPORTANCE TheinnateimmuneDNAcytosinedeaminaseAPOBEC3B(A3B)accountsforalargeproportionofsomaticmuta-
tionsincervicalandhead/neckcancers,butnothingisknownaboutthemechanismresponsibleforitsupregulationinthese
tumortypes.Almostallcervicalcarcinomasandlargeproportionsofhead/necktumorsarecausedbyhumanpapillomavirus
(HPV)infection.Here,weestablishamechanisticlinkbetweenHPVinfectionand A3Bupregulation.TheE6oncoproteinof
high-risk,butnotlow-risk,HPVtypestriggers A3Bupregulation,supportingamodelinwhichTP53inactivationcausesadere-
pressionofA3BgenetranscriptionandelevatedA3Benzymelevels.Thisvirus-inducedmutatorphenotypeprovidesamechanis-
ticexplanationforA3BsignaturemutationsobservedinHPV-positivehead/neckandcervicalcarcinomasandmayalsohelpto
accountforthepreferentialcancerpredispositioncausedbyhigh-riskHPVisolates.
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S
even APOBEC3 (A3) enzymes have broad and overlapping
functions in innate immunity by restricting viruses, trans-
posons,andotherforeignDNAelements(reviewedinreferences1
to 3). These proteins are part of a larger family that includes the
DNA deaminase AID and the RNA editing protein APOBEC1,
which also have specialized functions in antibody diversiﬁcation
and APOB mRNA editing, respectively, (reviewed in references 4
and 5). The deﬁning activity of all members of this protein family
issingle-strandedDNAcytosine-to-uracil(C-to-U)deamination,
as even APOBEC1 prefers DNA over RNA cytosines (6–8). The
current working model for HIV-1 restriction illustrates the over-
lapping antiviral activities of these enzymes (reviewed in refer-
ences 1 to 3). In a Trojan horse-like mechanism, A3D, A3F, A3G,
and A3H (not A3A, A3B, or A3C) speciﬁcally package into bud-
ding viral particles, breach the viral core during maturation, and
deaminateviralcDNAcytosinesduringreversetranscription.The
resulting uracils template the addition of genomic-strand ade-
nines and account for the well-known phenomenon of viral
G-to-A hypermutation often observed in clinical isolates. A3D,
A3F, and A3H are responsible for mutations in GA-to-AA dinu-
cleotide contexts, whereas A3G accounts for mutations in GG-
to-AG contexts (illustrating the distinct local speciﬁcity of these
RESEARCH ARTICLE crossmark
November/December 2014 Volume 5 Issue 6 e02234-14
® mbio.asm.org 1enzymes for 5= TC and 5= CC substrates). Remarkably, a single
HIV-1 protein, Vif, is able to physically bind and counteract all
fouroftheserestrictionfactorsbyrecruitinganE3ubiquitinligase
complex to target them for proteasomal degradation. Based on
evidenceforrestrictionand/orG-to-Amutation,otherpotentially
A3-susceptible human viruses include adeno-associated virus
(AAV),Epstein-Barrvirus(EBV),hepatitisBvirus(HBV),herpes
simplex virus 1 (HSV-1), human T-cell lymphotropic virus
(HTLV), and, most relevant to this study, human papillomavirus
(HPV) (9–13; reviewed in reference 14).
HPVisan~8-kbdouble-strandedDNAvirusthatreplicatesin
the nucleus of mucosal or cutaneous keratinocytes (reviewed in
reference 15). Over 170 HPV types have been identiﬁed thus far,
andthesecanbeclassiﬁedintohigh-andlow-riskgroupsbasedon
carcinogenicrisk(16–18).HPVinfectionisnecessarybutnotsuf-
ﬁcient for the development of cervical cancer, and it is also
strongly associated with other anogenital and a growing subset of
head/neck squamous cancers (19, 20). The viral oncoproteins E6
and E7 are invariably expressed in HPV-positive cancers (21, 22),
and the expression of these proteins from high-risk isolates is suf-
ﬁcient to immortalize human keratinocytes (23, 24). The most
critical functions of E6 and E7, respectively, are thought to be
functional inactivation of tumor suppressors TP53 and RB (25–
28).
Recently, the enzymatic activity of A3B has been implicated as
a major source of mutagenesis in multiple human cancers (29–
37). A3B is a nuclear enzyme and the only detectable source of
single-strandedDNAcytosinedeaminaseactivityinmultiplecan-
cer cell lines (29, 32). A3B mRNA levels are upregulated in many
cancer types, including those of the breast, bladder, cervix, lung,
head/neck, and ovary (29–32). The trinucleotide preference of
A3B (5= TCA and 5= TCG) is highly enriched in the mutation
spectrumofthesecancertypes(29–32).Moreover,positivecorre-
lations are evident between A3B mRNA levels and somatic muta-
tion loads (30–32). Interestingly, head/neck and cervical cancers
are among the tumor types displaying the highest A3B expression
levels and cytosine mutational loads in A3B-preferred trinucle-
otide contexts (30, 31). Overall, a compelling case has been made
for A3B mutagenesis in multiple human cancers.
GiventhefactthatA3Bisexpressedatlowlevelsornotatallin
most normal tissues (29, 30, 38), a major unresolved question is
how it becomes upregulated in cancer. Since A3B is a member of
the A3 family of innate immune effector proteins with demon-
stratedantiviralactivities(thoughnotagainstHIV-1inTlympho-
cytes [39, 40]) and given the tendency of HPV-associated cancers
of the head/neck and cervix to be among the highest A3B-
impacted tumor types, here we test the hypothesis that HPV di-
rectly causes A3B mRNA upregulation. Moreover, because E6 is
invariably expressed in HPV-positive tumors (21, 22) and A3B
upregulation is associated with genetic inactivation of TP53 (29),
we tested the speciﬁc hypothesis that E6 is the primary trigger of
A3B upregulation in virus-positive tumor types.
RESULTS
HPV genomic DNA causes A3B upregulation. We ﬁrst tested
whether high-risk HPV genomes could trigger A3B upregulation.
Normalimmortalizedkeratinocytes(NIKS)weretransfectedwith
full-length HPV16 or HPV18 genomes. Pools of transfectants
wereselectedandexpandedtoallowforestablishmentoftheviral
genomes as nuclear plasmids and viral gene expression, and then
reverse transcription-quantitative PCR (RT-qPCR) was used to
quantify A3B mRNA levels. In comparison to a control vector-
transfectedpoolofNIKSestablishedinparallel,A3BmRNAlevels
were induced signiﬁcantly by transfection of either HPV16 or
HPV18 genomes (Fig. 1A). HPV18 genomic DNA consistently
caused higher levels of A3B induction, routinely 5- to 10-fold
above the negative control.
To ask whether the effect of HPV genomic DNA is speciﬁc to
A3Bortoamoregeneralantiviralresponse,RT-qPCRassayswere
used to quantify expression of all A3 family members (Fig. 1A).
Most of these genes, including A3A, A3D, A3H, AID, A1, A2, and
A4, were expressed at very low or undetectable levels and not
affected by HPV genomic DNA transfection. Two family mem-
bers,A3FandA3G,wereexpressedatsimilarlevelsinbothcontrol
and HPV-transfected NIKS. The only exception was A3C, which
showed an inverse relationship with higher levels in control-
transfected cells and lower levels in HPV-transfected cells, espe-
cially with HPV18 genomic DNA. Thus, A3B is the only DNA
deaminase family member upregulated at the level of transcrip-
tion in NIKS harboring HPV genomes. Since there are no com-
mercial antibodies for A3B, the current gold standard for detect-
ing A3B protein levels is by quantifying its functional activity (29,
32). Therefore, we performed single-stranded DNA deaminase
assaysusingproteinextractsfromthesamecellsasusedformRNA
quantiﬁcation (Fig. 1B). As expected, protein extracts produced
from cells transfected with HPV18 had deaminase activity more
than ﬁve times higher than that of the transfection control (68%
versus 12% substrate deamination, respectively). These results
show that transfection of HPV18 genome results in an increase in
DNA deaminase activity that is proportional to the increase ob-
served for A3B mRNA.
HPV E6 is sufﬁcient for A3B upregulation. Considering that
the viral oncoproteins are invariably expressed in HPV-positive
tumors, we next tested for a possible role of E6 in A3B upregula-
tion. NIKS were transfected either with the full-length HPV18
genome or with a full-length HPV18 genome containing a stop
codonwithintheE6openreadingframe(HPV18E6-STOP)(41).
As shown above, transfection with the wild-type HPV18 genome
resulted in a signiﬁcant upregulation of A3B mRNA levels. How-
ever,mostofthiseffectwaslostupontransfectionwiththeHPV18
genome containing an E6-STOP mutation, indicating that E6 is
requiredforinductionofA3B(Fig.2A).E6mRNAlevelswerealso
reduced likely due to nonsense-mediated decay (Fig. 2B). To re-
conﬁrm the correlation between upregulation of A3B mRNA lev-
elsandenzymaticactivity,DNAdeaminaseassayswereperformed
using cell extracts. As expected, the DNA cytosine deaminase ac-
tivity induced by transfection with wild-type HPV18 genome was
ablated by inactivation of E6 (Fig. 2C).
To test if expression of E6 is sufﬁcient to induce A3B upregu-
lation, we used a panel of transduced cell lines based on the
hTERT-immortalized keratinocyte cell line N/TERT-1. Each line
expressedadifferentE6proteinfromagenusalphahigh-risktype
(HPV16,-18,-33,-45,and-52),alow-risktype(HPV6band-11),
oratypewithnoknowncancerassociation(HPV2aand-57)(42,
43). Interestingly, only cells expressing high-risk E6 proteins
showed signiﬁcant increases in A3B mRNA levels in comparison
toanemptyvectorcontrolandE6fromlow-riskandnon-cancer-
associated HPV types (P  0.01; Fig. 3).
We next asked if these results extended to primary keratino-
cytes. Early-passage human keratinocyte G5-Ep cells were trans-
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differentHPVtypes.Asabove,A3Bupregulationwasinducedand
high-riskE6proteinscausedhigherlevelsofinduction(P0.05)
(seeFig.S1inthesupplementalmaterial).Together,thedatawith
NIKS, N/TERT-1, and early-passage keratinocytes demonstrate
that E6 alone, especially from high-risk HPV types, is sufﬁcient to
induce A3B upregulation.
E6 is required for endogenous A3B expression in HPV-
positivecancercelllines.TotestifendogenousE6couldcontrib-
ute to upregulation of endogenous A3B, we depleted the HPV
earlytranscriptfromtheHPV16-positiveCaSkicellline.Twodif-
ferent small interfering RNAs (siRNAs) were used to interfere
with E6 expression. In each instance, the level of E6 depletion was
proportional to the decrease in endogenous A3B mRNA levels
with an approximately 3-fold reduction in E6 mRNA levels and a
corresponding 3-fold reduction in A3B mRNA levels (Fig. 4).
These results indicate that endogenous E6 contributes to upregu-
lation of endogenous A3B.
Increased levels of A3B in HPV-positive head and neck tu-
mors.Finally,weaskediftheobservedrelationshipbetweenHPV
status and A3B levels occurs in vivo. TCGA RNA sequencing
(RNA-seq) data from head and neck cancers with reported HPV
status were analyzed for A3B mRNA levels relative to the house-
keeping gene TBP. Using TCGA clinical data, we were able to
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FIG 1 APOBEC3B upregulation by transfection of full-length HPV genomes. (A) Histograms reporting APOBEC family member mRNA levels in NIKS
transfected with a full-length HPV16 or HPV18 or a control plasmid (Cont.). Each histogram bar shows the mean expression level of each APOBEC family
member normalized to TBP (error bars report standard deviations from triplicate assays). (B) Image of the results of a representative DNA cytosine deaminase
assayperformedwithcellextractsfromthesamecellsasinpanelA.Thesingle-strandedDNAsubstratewastreatedwithreactionbufferasanegativecontrol()
and recombinant APOBEC3A as a positive control ().
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69 of the HPV-negative patients. A3B mRNA levels were signiﬁ-
cantlyincreasedinHPV-positivecomparedtoHPV-negativecan-
cers (P  0.0006) (Fig. 5A). Notably, a signiﬁcant increase in A3B
expression was evident for the subset of HPV-positive patients
with no smoking history (n  6) compared to corresponding
HPV-negative nonsmokers (n  10; P  0.0013).
DISCUSSION
This is the ﬁrst study to demonstrate a mechanistic link between
HPV infection and upregulation of the DNA cytosine deaminase
A3B. Here we show that transfection of the HPV genome triggers
A3BupregulationandthatE6expressionisrequired.A3Bupregu-
lation is apparent at both mRNA and activity levels. We demon-
stratethathigh-riskE6aloneissufﬁcientfortheinductionofA3B
in keratinocytes and that continuous expression of E6 is required
to maintain higher A3B levels in HPV-positive cancer cell lines.
Finally, analyses of available TCGA data show that A3B levels are
higher in head/neck HPV-positive cancers than in HPV-negative
cancers. Taken together, these results suggest a model in which
high-risk HPV E6 induces A3B gene expression, leading to a mu-
tator phenotype and the observed cytosine mutation biases in
HPV-positive head/neck and cervical cancers.
A3B has been strongly implicated in mutagenesis in a wide
variety of human cancers (29–37). Given its relatively low expres-
sion level in almost all normal tissues (29, 30, 38), a major ques-
tion is how A3B upregulation occurs in cancer cells. As described
here, the E6 oncoprotein provides the ﬁrst mechanistic link be-
tween viral infection and A3B-mediated cancer mutagenesis. Al-
though E6 has numerous functions, we propose a direct model in
which high-risk E6 proteins inactivate TP53 and cause derepres-
sion of A3B gene transcription. This mechanism has the potential
to explain A3B upregulation in HPV-positive cervical and head/
neck cancers (and possibly other cancers such as some bladder
carcinomas where HPV may also contribute [19, 20, 44]). This
connection between TP53 function and A3B upregulation is sup-
ported by our previous observation that genetic inactivation of
TP53correlatespositivelywithelevatedA3Blevelsinbreastcancer
cell lines and primary tumors (29). Therefore, a model involving
TP53 inactivation may apply more generally and contribute to
tumorigenesis on at least two distinct levels, by elevating levels of
DNA damage and mutation through A3B and by preventing the
DNAdamageresponseandapoptosis.Additionalstudiesarenec-
essary to distinguish between this model and other, less-direct
possibilitiessuchasanassociationofE6withcellularPDZdomain
proteins, a characteristic that is also shared by genus alpha high-
risk E6 proteins (45, 46). These E6 proteins have a PDZ-binding
domain that interacts with a number of PDZ targets with a wide
array of functions, including cell signaling, polarity determina-
tion, and cell proliferation (reviewed in references 47 and 48).
AlthoughE6andE7aresufﬁcienttoimmortalizeprimaryker-
atinocytes(23,24),completecellulartransformationalsorequires
the introduction of additional activated oncogenes or extensive
periods of cell culture (49–51). These observations strongly sug-
gest that additional somatic mutations are required for transfor-
mation(reviewedinreference52).WehypothesizethatE6expres-
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stochastic, mutational process that leads eventually to transfor-
mation.Thesamedeaminationprocessmayalsoexplaingenomic
instability phenotypes previously shown to be inducible by high-
risk E6 oncoproteins (reviewed in reference 52).
Our data provide evidence that HPV infection causes upregu-
lation of A3B, a phenomenon generally regarded as an innate an-
tiviral response and previously observed for HIV-1 infection of
primary T lymphocytes (1, 39, 40). This relationship prompts the
additionalquestionofhowHPVavoidsrestrictioninthepresence
of increased A3B activity and constitutive levels of other A3 pro-
teins.Despitethefactthatoverexpressionstudieshaveshownthat
HPV can be mutated by APOBEC3 (A/C/H) (11, 53), clinical iso-
latesrarelyshowevidenceforhypermutation(11),consistentwith
an effective APOBEC3 counteraction or avoidance strategy oper-
ating in vivo. Based on precedents with other viruses (notably
lentiviruses and foamy viruses [reviewed in reference 1]), the an-
swer to this question may provide fundamental mechanistic in-
sights into the HPV replication and transmission cycle. Finally,
the robust cellular response to HPV infection characterized by
A3B upregulation strongly suggests that other viruses may also be
able to provoke similar responses. A mechanistic linkage to the
innate antiviral response may also help to explain A3B upregula-
tion and genomic mutagenesis observed in other cancers such as
those of the lung, bladder, and breast tissues.
MATERIALS AND METHODS
Cell lines. Normal immortal keratinocytes (NIKS; provided by Lynn
Allen-Hoffman [54]) were cultured in E medium supplemented with
24 g/ml adenine, 8.4 g/ml cholera toxin, 10 ng/ml epidermal growth
factor (EGF), 400 ng/ml hydrocortisone, 5 g/ml insulin, 1% penicillin-
streptomycin, and 5% fetal bovine serum and grown in the presence of
mitomycin C-treated J2-3T3 feeder cells (55).
Human hTERT-immortalized keratinocytes (N/TERT-1) and G5-Ep
primary human foreskin keratinocytes (provided by James Rheinwald
[56–58]) were cultured in keratinocyte serum-free medium (K-SFM)
supplementedwith0.3mMCaCl2,0.2ng/mlEGF,25g/mlbovinepitu-
itary extract, and 1% penicillin-streptomycin.
HPVgenometransfections.NIKSweretransfectedwiththeHPVge-
nome as described previously (41). Full-length HPV genomes from wild-
type HPV16 and HPV18 and from HPV18 containing a stop codon at E6
(E6-STOP)wereexcisedfromtheirbacterialvectorswitheitherBamHIor
NcoI and recircularized with T4 DNA ligase (15 U/l) at a concentration
of 8 ng/l DNA. One day prior to transfection, 3  105 NIKS were plated
inlow-Ca2incompleteEmediumintheabsenceofJ2-3T3feeders.Cells
were transfected with 3 g of religated HPV and 1.2 g of a plasmid
conferring neomycin resistance (pEGFP-N1) using Effectene (Qiagen).
HPV-negative controls were transfected with 1.2 g of pEGFP-N1 alone.
The next day, cells were transferred to a 10-cm dish containing J2-3T3
feeders. Cells were selected for 4 days in the presence of G418 (125 g/ml
for 2 days followed by 250 g/ml for 2 days). Two to 3 weeks after trans-
fection, colonies were pooled and expanded. Cells were passaged on a
weekly basis and were grown until approximately 90% conﬂuent prior to
harvesting of total RNA.
Retroviral transductions. N/TERT-1 and G5-Ep primary keratino-
cytesstablyexpressingHPV16E6havebeendescribedelsewhere(42,43).
Cellsweretransducedwithapanelofretroviruses(pMSCV-N-HA-IRES-
PURO)expressingE6fromgenusalphahigh-risktypes(HPV16,-18,-33,
-45,and-52),fromlow-risktypes(HPV6band-11),orfromtypeswithno
known cancer association (HPV2a and -57) (42). As a negative control,
cells were transduced with the empty vector (pMSCV-N-HA-IRES-
PUROempty).Cellswereselectedwithpuromycinandgrowntoapprox-
imately 30% conﬂuence prior to harvesting of total RNA. Expression dif-
ferences were assessed using a two-tailed Student t test.
siRNAtransfections.CaSkicellsweretransfectedusingDharmaFECT
1 (Dharmacon/GE Life Sciences) as described elsewhere (59). siRNA du-
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FIG 5 APOBEC3B overexpression in HPV-positive head/neck tumors. (A)
A3B mRNA levels in HPV-positive and HPV-negative head/neck cancers
(HPV positive, n  69; HPV negative, n  23; P  0.0006). (B) A3B mRNA
levels in the subset of patients in panel A reported as never-smokers (HPV
positive,n6;HPVnegative,n10;P0.0013).Eachhistogrambarshows
theaverageA3BexpressionlevelnormalizedtoTBP,withvaluesderivedfrom
TCGA RNA-seq data sets (error bars report the standard deviations).
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® mbio.asm.org 5plexes used were as follows: nontargeting siRNA (Dharmacon/GE Life
Sciences D-001810-01) and two custom-designed siRNAs targeting the
HPV16 early transcript. SiGLO red transfection indicator (Dharma-
con/GELifeSciencesD-0011630-02)wasusedtovisualizeefﬁcienttrans-
fection in a control well. Sequences of the custom siRNAs are as follows:
HPV16 #1, CAACAUUAGAACAGCAAUAUU, and HPV16 #2, GGACA
GAGCCCAUUACAAUUU. siRNAs were used at a ﬁnal concentration of
40 nM. Cells were harvested at 72 h posttransfection.
Quantiﬁcation of cellular and viral RNA. Reverse transcription-
quantitative PCR (RT-qPCR) was used to measure APOBEC and E6
mRNA levels as described previously (38). Total RNA was isolated using
the NucleoSpin RNA kit (Clontech). One microgram from each sample
wasreversetranscribedwiththecDNATranscriptorreversetranscriptase
kit (Roche; catalog no. 03531287001). qPCR was performed using 2
master mix (Roche; catalog no. 04887301001). Primer and probe sets
(Universal Probe Library; Roche) for HPV E6 were as follows: 16E6-F,
5=-GCACCAAAAGAGAACTGCAA; 16E6-R, 5=-TGTTTGCAGCTCTG
TGCATAA; UPL#115; 18E6-F, 5=-ACATTGGAAAAACTAACTAACAC
TGG; 18E6-R, 5=-TCGTTTTTCATTAAGGTGTCTAAGTTT; UPL#120.
For each condition, qPCRs were performed in triplicate, mRNA expres-
sion levels were normalized to those of the housekeeping gene TBP
mRNA, and the mean and standard deviation were reported.
DNA deaminase activity assays. Deamination reactions were per-
formed at 37°C for 2 h using 16.5 l of cell extract, 4 pmol of oligonucle-
otide (5=-ATTATTATTATTCAAATGGATTTATTTATTTATTTATTTA
TTT-ﬂuorescein),0.025UuracilDNAglycosylase(UDG),2l10UDG
buffer (NEB), and 1.75 U RNase A. Reaction mixtures were treated with
100 mM NaOH at 95°C for 10 min to achieve complete backbone break-
age.Reactionmixtureswereseparatedon15%Tris-borate-EDTA(TBE)–
urea gels to separate substrate from product. Gels were scanned using a
Fujiﬁlm FLA-7000 image reader, and densitometry was performed using
ImageQuant TL (GE Healthcare Life Science).
Headandneckcancerdataretrievalandanalyses.Head/neckcancer
data were acquired from The Cancer Genome Atlas (TCGA) (60), and
individuals were selected for analysis if HPV status was clear. RNA-seq
counts were used to quantify A3B mRNA expression levels and calculate
abundancerelativetoTBP.Thismetricfacilitatescross-comparisonswith
RT-qPCRdatasimilarlynormalized.Expressiondifferenceswereassessed
usingatwo-tailedStudentttest.Resultswereconsideredsigniﬁcantifthe
calculated P value was under 0.05.
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